PharmaCyte Biotech Provides Update for February 7th Shareholder Call
February 02 2017 - 9:00AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing therapies for cancer
and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, announced today that during its
upcoming shareholder call PharmaCyte’s Chief Executive Officer,
Kenneth L. Waggoner, will update shareholders on PharmaCyte’s
clinical trial development program for pancreatic cancer and
respond to questions submitted by shareholders. Also, Mr. Waggoner
will discuss the status of the progress being made by PharmaCyte to
develop a therapy for malignant ascites, a therapy for diabetes and
a therapy for rare and difficult to treat diseases using the
constituents of the Cannabis plant knows as “cannabinoids.”
PharmaCyte appreciates the questions that have
been submitted and, as of the time of this press release, the
window for submitting questions has closed.
Mr. Waggoner commented, “We are looking forward
to our second shareholder call. These are exciting times at
PharmaCyte, and I look forward to sharing information about
PharmaCyte's clinical development program and respond to the
questions submitted by shareholders. Also, I will highlight what we
have been working on in the areas of a therapy for malignant
ascites, a therapy for Type 1 and insulin-dependent Type 2 diabetes
and a therapy for other diseases using cannabinoids rather than
traditional chemotherapy agents.”
The shareholder call is scheduled for:
Date: |
February 7, 2017 |
Time: |
4:30 p.m. EST |
Telephone Number:
|
(515) 739-1030 |
Access Code: |
915-603-449 |
An audio replay will be available. PharmaCyte
will provide a telephone number and access code to listen to the
recorded call the next day.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage
biotechnology company developing therapies for cancer and diabetes
based upon a proprietary cellulose-based live cell encapsulation
technology known as “Cell-in-a-Box®”. This technology will be used
as a platform upon which therapies for several types of cancer and
diabetes are being developed. PharmaCyte’s therapy for cancer
involves encapsulating genetically engineered human cells that
convert an inactive chemotherapy drug into its active or
“cancer-killing” form. These encapsulated cells are implanted as
close to the patient’s cancerous tumor as possible. Once
implanted, a chemotherapy drug that is normally activated in the
liver (ifosfamide) is given intravenously at one-third the normal
dose. The ifosfamide is carried by the circulatory system to where
the encapsulated cells have been implanted. When the ifosfamide
comes in contact with the encapsulated cells they act as an
artificial liver and activate the chemotherapy drug at the source
of the cancer. This “targeted chemotherapy” has proven effective
and safe to use in past clinical trials and results in little to no
side effects.
In addition to developing a novel therapy for
cancer, PharmaCyte is developing a treatment for Type 1 diabetes
and insulin-dependent Type 2 diabetes. PharmaCyte plans to
encapsulate a human cell line that has been genetically engineered
to produce, store and release insulin in response to the levels of
blood sugar in the human body. The encapsulation will be done using
the Cell-in-a-Box® technology. Once the encapsulated cells are
implanted in a diabetic patient they will function as a
“bio-artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release may contain forward-looking
statements regarding PharmaCyte and its future events and results
that involve inherent risks and uncertainties. The words
"anticipate", "believe", "estimate", "expect", "intend", "plan" and
similar expressions, as they relate to PharmaCyte or its
management, are intended to identify forward-looking statements.
Important factors, many of which are beyond the control of
PharmaCyte, could cause actual results to differ materially from
those set forth in the forward-looking statements. They include
PharmaCyte's ability to continue as a going concern, delays or
unsuccessful results in preclinical studies and clinical trials,
flaws or defects regarding its product candidates, changes in
relevant legislation or regulatory requirements, uncertainty of
protection of PharmaCyte’s intellectual property and PharmaCyte’s
continued ability to raise capital. PharmaCyte does not assume any
obligation to update any of these forward-looking
statements.
More information about PharmaCyte can be found
at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com